Charles Rhyee
Stock Analyst at TD Cowen
(2.05)
# 3,117
Out of 5,182 analysts
78
Total ratings
43.4%
Success rate
-6.21%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Upgrades: Buy | $15 | $9.63 | +55.76% | 5 | Mar 9, 2026 | |
| IQV IQVIA Holdings | Upgrades: Buy | $174 → $213 | $160.68 | +32.56% | 4 | Mar 9, 2026 | |
| VEEV Veeva Systems | Maintains: Buy | $380 → $300 | $156.15 | +92.12% | 5 | Mar 5, 2026 | |
| TDOC Teladoc Health | Maintains: Hold | $8 → $6 | $5.70 | +5.26% | 7 | Feb 26, 2026 | |
| CRL Charles River Laboratories International | Maintains: Buy | $251 → $235 | $167.74 | +40.10% | 7 | Feb 20, 2026 | |
| TALK Talkspace | Maintains: Buy | $6 → $9 | $5.17 | +74.08% | 3 | Feb 20, 2026 | |
| ICLR ICON Public Limited Company | Upgrades: Buy | $183 → $120 | $106.34 | +12.85% | 7 | Feb 18, 2026 | |
| MEDP Medpace Holdings | Upgrades: Hold | $462 → $419 | $393.42 | +6.50% | 7 | Feb 18, 2026 | |
| CI The Cigna Group | Maintains: Buy | $333 → $338 | $279.72 | +20.84% | 2 | Feb 9, 2026 | |
| MCK McKesson | Maintains: Buy | $1,000 → $1,012 | $836.10 | +21.04% | 5 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $46.23 | -0.50% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $2.30 | +160.87% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $400 | $311.39 | +28.46% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $100 | $78.86 | +26.81% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $183 → $225 | $204.72 | +9.91% | 3 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $27 | $28.54 | -5.40% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $100 → $50 | $6.10 | +719.67% | 3 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $56 | $5.25 | +966.67% | 2 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $360 → $280 | $7.20 | +3,788.89% | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $2.95 | +1,594.92% | 2 | Jun 21, 2022 |
Fortrea Holdings
Mar 9, 2026
Upgrades: Buy
Price Target: $15
Current: $9.63
Upside: +55.76%
IQVIA Holdings
Mar 9, 2026
Upgrades: Buy
Price Target: $174 → $213
Current: $160.68
Upside: +32.56%
Veeva Systems
Mar 5, 2026
Maintains: Buy
Price Target: $380 → $300
Current: $156.15
Upside: +92.12%
Teladoc Health
Feb 26, 2026
Maintains: Hold
Price Target: $8 → $6
Current: $5.70
Upside: +5.26%
Charles River Laboratories International
Feb 20, 2026
Maintains: Buy
Price Target: $251 → $235
Current: $167.74
Upside: +40.10%
Talkspace
Feb 20, 2026
Maintains: Buy
Price Target: $6 → $9
Current: $5.17
Upside: +74.08%
ICON Public Limited Company
Feb 18, 2026
Upgrades: Buy
Price Target: $183 → $120
Current: $106.34
Upside: +12.85%
Medpace Holdings
Feb 18, 2026
Upgrades: Hold
Price Target: $462 → $419
Current: $393.42
Upside: +6.50%
The Cigna Group
Feb 9, 2026
Maintains: Buy
Price Target: $333 → $338
Current: $279.72
Upside: +20.84%
McKesson
Feb 5, 2026
Maintains: Buy
Price Target: $1,000 → $1,012
Current: $836.10
Upside: +21.04%
Jan 12, 2026
Initiates: Buy
Price Target: $46
Current: $46.23
Upside: -0.50%
Nov 10, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.30
Upside: +160.87%
Nov 10, 2025
Maintains: Buy
Price Target: $350 → $400
Current: $311.39
Upside: +28.46%
Nov 3, 2025
Maintains: Buy
Price Target: $99 → $100
Current: $78.86
Upside: +26.81%
Nov 3, 2025
Maintains: Buy
Price Target: $183 → $225
Current: $204.72
Upside: +9.91%
Nov 3, 2025
Maintains: Hold
Price Target: $30 → $27
Current: $28.54
Upside: -5.40%
Mar 23, 2023
Downgrades: Market Perform
Price Target: $100 → $50
Current: $6.10
Upside: +719.67%
Oct 20, 2022
Maintains: Outperform
Price Target: $70 → $56
Current: $5.25
Upside: +966.67%
Aug 16, 2022
Maintains: Outperform
Price Target: $360 → $280
Current: $7.20
Upside: +3,788.89%
Jun 21, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $2.95
Upside: +1,594.92%